FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.
What happened
FDA inspected Shimoga Chemicals' drug manufacturing facility in Sangli, India, from January 19 to 23, 2026, and found significant deviations from CGMP, the FDA's current good manufacturing practice rules for drugs. Investigators found unreported laboratory sample injections, including an out-of-specification strength result for clomiphene citrate USP batch CC/005/24-25 that was released and distributed, plus inadequate sampling, method verification, process validation, cleaning, quality-unit investigations, stability, and training. The firm recalled clomiphene citrate USP on May 14, 2026, and FDA placed its drugs on Import Alert 66-40 on June 2, 2026.
What FDA found
The firm did not record some laboratory sample injections, including an out-of-specification strength result for batch CC/005/24-25, which was released and distributed.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Batch records did not specify sample quantities, locations, methods, or timing, and samples were taken from arbitrary locations.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The firm did not verify any test methods, including the residual solvent method used by its contract laboratory.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Process validation reports did not reflect actual manufacturing and did not address hold times.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)Cleaning procedures for shared equipment lacked defined acceptance criteria, specific methods, materials, contact times, and validation.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The quality unit did not adequately investigate out-of-specification events, ensure stability data supported expiry, or ensure personnel were trained.
21 CFR parts 210 and 211
What FDA wants
FDA asks Shimoga Chemicals to correct the deviations promptly and provide comprehensive assessments and remediation plans for its laboratory, validation, cleaning, quality-unit, stability, training, and data-integrity failures, and to engage a qualified CGMP consultant before resuming U.S. manufacturing; the provided letter text does not show a response deadline.
Who should pay attention
- compounding pharmacies using clomiphene citrate USP
- API buyers and distributors
- quality teams auditing suppliers
This is a summary. Read the original letter on fda.gov.